Your fact-checks will appear here
The decline in cognitive function, including memory and learning, potentially linked to cadmium exposure.
Medical and experts interviewed in the press and noted in analyses frame ’s long-term risks along three axes: a recently disclosed that carries mostly manageable risks (experts say it is rarely life‑t...
A positive amyloid PET in an older adult without symptoms means the scan has detected fibrillar amyloid plaques—an AD-related pathology that increases lifetime risk of cognitive decline but does not b...
Mind-boosting supplements marketed to improve memory, focus, or clarity are a crowded, where product claims often outpace evidence and safety testing; some products have been found to contain unapprov...
commonly cause muscle-related complaints—ranging from mild myalgia to rare rhabdomyolysis—and carry a small but real increased risk of new-onset diabetes; other reported harms (liver enzyme elevations...
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
Yes — a growing body of laboratory, animal and human observational research shows : it crosses or disrupts the blood–brain barrier, accumulates in neural tissue, produces oxidative stress and neuroinf...
Randomized controlled trials (RCTs) and systematic reviews converge on a clear pattern: has produced cognitive benefits most consistently in people with mild cognitive impairment (), but large RCTs in...
Randomized and observational studies converge on a plausible protective effect of treating with against and—under some conditions—dementia, but the magnitude and causality remain unsettled: found subs...